{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:36:35Z","timestamp":1789565795470,"version":"build-2803163510"},"reference-count":109,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"am","delay-in-days":313,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL147392"],"award-info":[{"award-number":["HL147392"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI155664"],"award-info":[{"award-number":["R01 AI155664"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21 AI153201"],"award-info":[{"award-number":["R21 AI153201"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Tuberculosis"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.tube.2022.102268","type":"journal-article","created":{"date-parts":[[2022,10,4]],"date-time":"2022-10-04T02:24:01Z","timestamp":1664850241000},"page":"102268","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice"],"prefix":"10.1016","volume":"137","author":[{"given":"Divya","family":"Sriram","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rishi","family":"Wahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily C.","family":"Maggioncalda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandra M.","family":"Panthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2214-0114","authenticated-orcid":false,"given":"Gyanu","family":"Lamichhane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tube.2022.102268_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1164\/rccm.200604-571ST","article-title":"An official ATS\/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases","volume":"175","author":"Griffith","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2022.102268_bib2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1164\/rccm.201405-0884OC","article-title":"Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk","volume":"190","author":"Adjemian","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2022.102268_bib3","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1001\/archderm.142.10.1287","article-title":"Skin and soft tissue infections due to rapidly growing mycobacteria: comparison of clinical features, treatment, and susceptibility","volume":"142","author":"Uslan","year":"2006","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.tube.2022.102268_bib4","doi-asserted-by":"crossref","first-page":"84","DOI":"10.5021\/ad.2009.21.1.84","article-title":"A case of skin and soft tissue infection caused by Mycobacterium abscessus","volume":"21","author":"Kwon","year":"2009","journal-title":"Ann Dermatol"},{"key":"10.1016\/j.tube.2022.102268_bib5","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000000861","article-title":"Disseminated Mycobacterium abscessus infection following septic arthritis: a case report and review of the literature","volume":"94","author":"Fukui","year":"2015","journal-title":"Medicine (Baltim)"},{"key":"10.1016\/j.tube.2022.102268_bib6","doi-asserted-by":"crossref","DOI":"10.3201\/2109.141634","article-title":"Mycobacterium abscessus complex infections in humans","volume":"21","author":"Lee","year":"2015","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib7","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/j.jiac.2021.05.003","article-title":"Disseminated Mycobacterium abscessus subspecies massiliense infection and subsequent prosthetic joint infection in a hemodialysis patient: a case report","volume":"27","author":"Tsuruyama","year":"2021","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib8","doi-asserted-by":"crossref","first-page":"67","DOI":"10.3389\/fmicb.2018.00067","article-title":"Phylogenomics and comparative genomic studies robustly support division of the genus Mycobacterium into an emended genus Mycobacterium and four novel genera","volume":"9","author":"Gupta","year":"2018","journal-title":"Front Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib9","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.1099\/ijsem.0.001376","article-title":"Emended description of Mycobacterium abscessus, Mycobacterium abscessus subsp. abscessus and Mycobacterium abscessus subsp. bolletii and designation of Mycobacterium abscessus subsp. massiliense comb. nov","volume":"66","author":"Tortoli","year":"2016","journal-title":"Int J Syst Evol Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib10","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.659997","article-title":"Mycobacterium abscessus complex: a review of recent developments in an emerging pathogen","volume":"11","author":"Victoria","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib11","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1164\/rccm.201003-0395OC","article-title":"Clinical significance of differentiation of Mycobacterium massiliense from Mycobacterium abscessus","volume":"183","author":"Koh","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2022.102268_bib12","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1164\/rccm.201002-0310OC","article-title":"Nontuberculous mycobacterial lung disease prevalence at four integrated health care delivery systems","volume":"182","author":"Prevots","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.tube.2022.102268_bib13","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1513\/AnnalsATS.201709-727OC","article-title":"Epidemiology of pulmonary nontuberculous mycobacterial sputum positivity in patients with cystic fibrosis in the United States, 2010-2014","volume":"15","author":"Adjemian","year":"2018","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.tube.2022.102268_bib14","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/s41579-020-0331-1","article-title":"Non-tuberculous mycobacteria and the rise of Mycobacterium abscessus","volume":"18","author":"Johansen","year":"2020","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib15","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciaa241","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"71","author":"Daley","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib16","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.chest.2021.07.035","article-title":"Treatment of Mycobacterium abscessus pulmonary disease","volume":"161","author":"Griffith","year":"2022","journal-title":"Chest"},{"key":"10.1016\/j.tube.2022.102268_bib17","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2017-210929","article-title":"British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD)","volume":"72","author":"Haworth","year":"2017","journal-title":"Thorax"},{"key":"10.1016\/j.tube.2022.102268_bib18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1093\/cid\/ciq237","article-title":"Clinical and microbiologic outcomes in patients receiving treatment for Mycobacterium abscessus pulmonary disease","volume":"52","author":"Jarand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib19","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.chest.2017.04.166","article-title":"Microbiological and clinical outcomes of treating non-Mycobacterium avium complex nontuberculous mycobacterial pulmonary disease: a systematic review and meta-analysis","volume":"152","author":"Diel","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.tube.2022.102268_bib20","doi-asserted-by":"crossref","first-page":"9561","DOI":"10.1128\/AAC.01206-17","article-title":"Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence","volume":"61","author":"Pasipanodya","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib21","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01991-2018","article-title":"M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis","volume":"54","author":"Kwak","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.tube.2022.102268_bib22","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4103\/ijmy.ijmy_3_20","article-title":"Outcomes of pulmonary Mycobacterium abscessus infection","volume":"9","author":"Flight","year":"2020","journal-title":"Int J Mycobacteriology"},{"key":"10.1016\/j.tube.2022.102268_bib23","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1128\/CMR.05030-11","article-title":"Antimicrobial susceptibility testing, drug resistance mechanisms, and therapy of infections with nontuberculous mycobacteria","volume":"25","author":"Brown-Elliott","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.tube.2022.102268_bib24","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1093\/jac\/dkr578","article-title":"Mycobacterium abscessus: a new antibiotic nightmare","volume":"67","author":"Nessar","year":"2012","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib25","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1089\/mdr.2017.0286","article-title":"Activities of dual combinations of antibiotics against multidrug-resistant nontuberculous mycobacteria recovered from patients with cystic fibrosis","volume":"24","author":"Schwartz","year":"2018","journal-title":"Microb Drug Resist"},{"key":"10.1016\/j.tube.2022.102268_bib26","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/microorganisms7030090","article-title":"Mycobacterium abscessus: environmental bacterium turned clinical nightmare","volume":"7","author":"Lopeman","year":"2019","journal-title":"Microorganisms"},{"key":"10.1016\/j.tube.2022.102268_bib27","article-title":"Clinical efficacy and adverse effects of antibiotics used to treat Mycobacterium abscessus pulmonary disease","volume":"10","author":"Chen","year":"2019","journal-title":"Front Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib28","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3201\/eid2203.150828","article-title":"Treatment of Mycobacterium abscessus infection - volume 22, number 3\u2014march 2016 - emerging infectious diseases journal - CDC","volume":"22","author":"Novosad","year":"2016","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib29","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/mmi.13406","article-title":"A new piperidinol derivative targeting mycolic acid transport in Mycobacterium abscessus","volume":"101","author":"Dupont","year":"2016","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib30","doi-asserted-by":"crossref","first-page":"5876","DOI":"10.1021\/acs.jmedchem.7b00582","article-title":"Targeting mycolic acid transport by indole-2-carboxamides for the treatment of Mycobacterium abscessus infections","volume":"60","author":"Kozikowski","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.tube.2022.102268_bib31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.02245-18","article-title":"Indole-2-carboxamides are active against Mycobacterium abscessus in a mouse model of acute infection","volume":"63","author":"Pandya","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02548-19","article-title":"Synergistic interactions of indole-2-carboxamides and \u03b2-lactam antibiotics against Mycobacterium abscessus","volume":"64","author":"Raynaud","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib33","article-title":"Epetraborole is active against Mycobacterium abscessus","volume":"65","author":"Ganapathy","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009965","article-title":"Efficacy of epetraborole against Mycobacterium abscessus is increased with norvaline","volume":"17","author":"Sullivan","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.tube.2022.102268_bib35","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02752-16","article-title":"Activity of LCB01-0371, a novel oxazolidinone, against Mycobacterium abscessus","volume":"61","author":"Kim","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib36","doi-asserted-by":"crossref","first-page":"e01915","DOI":"10.1128\/AAC.01915-18","article-title":"In vitro and intracellular activity of imipenem combined with tedizolid, rifabutin, and avibactam against Mycobacterium abscessus","volume":"63","author":"Le Run","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib37","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s42003-020-01475-2","article-title":"Development of a penem antibiotic against Mycobacteroides abscessus","volume":"3","author":"Batchelder","year":"2020","journal-title":"Commun Biol"},{"key":"10.1016\/j.tube.2022.102268_bib38","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00039-22","article-title":"Penicillin binding proteins and \u03b2-lactamases of Mycobacterium tuberculosis: reexamination of the historical paradigm","volume":"7","author":"Kumar","year":"2022","journal-title":"mSphere"},{"key":"10.1016\/j.tube.2022.102268_bib39","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00536-22","article-title":"T405, a new penem, exhibits in vivo efficacy against M. abscessus and synergy with \u03b2-lactams imipenem and cefditoren","volume":"66","author":"Rimal","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib40","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1093\/jac\/dkz267","article-title":"Omadacycline as a promising new agent for the treatment of infections with Mycobacterium abscessus","volume":"74","author":"Bax","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib41","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02522-18","article-title":"In vitro activities of omadacycline against rapidly growing mycobacteria","volume":"63","author":"Shoen","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/AAC.00470-19","article-title":"In vitro activity of new tetracycline analogs omadacycline and eravacycline against drug-resistant clinical isolates of Mycobacterium abscessus","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib43","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.790767","article-title":"Omadacycline potentiates clarithromycin activity against Mycobacterium abscessus","volume":"12","author":"Bich Hanh","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.tube.2022.102268_bib44","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01947-20","article-title":"In vitro susceptibility testing of omadacycline against nontuberculous mycobacteria","volume":"65","author":"Brown-Elliott","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib45","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01704-21","article-title":"Potency of omadacycline against Mycobacteroides abscessus clinical isolates in vitro and in a mouse model of pulmonary infection","volume":"66","author":"Nicklas","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib46","first-page":"e02613","article-title":"Select \u03b2-lactam combinations exhibit synergy against Mycobacterium abscessus in vitro","volume":"63","author":"Story-Roller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib47","first-page":"e00614","article-title":"Synergistic efficacy of \u03b2-lactam combinations against Mycobacterium abscessus pulmonary infection in mice","volume":"63","author":"Story-Roller","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib48","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02545-20","article-title":"\u03b2-lactam combinations that exhibit synergy against Mycobacteroides abscessus clinical isolates","volume":"65","author":"Story-Roller","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib49","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/mBio.02895-18","article-title":"Dual \u03b2-lactam combinations highly active against Mycobacterium abscessus complex in vitro","volume":"10","author":"Pandey","year":"2019","journal-title":"mBio"},{"key":"10.1016\/j.tube.2022.102268_bib50","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1093\/cid\/ciab535","article-title":"One-two punch\u201d: synergistic \u00df-lactam combinations for Mycobacterium abscessus and target redundancy in the inhibition of peptidoglycan synthesis enzymes","volume":"73","author":"Nguyen","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib51","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dku510","article-title":"\u03b2-Lactamase inhibition by avibactam in Mycobacterium abscessus","volume":"70","author":"Dub\u00e9e","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/fmb-2016-0234","article-title":"Combinations of avibactam and carbapenems exhibit enhanced potencies against drug-resistant Mycobacterium abscessus","volume":"12","author":"Kaushik","year":"2017","journal-title":"Future Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib53","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02440-16","article-title":"Inhibition of the \u03b2-lactamase bla Mab by avibactam improves the in vitro and in vivo efficacy of imipenem against Mycobacterium abscessus","volume":"61","author":"Lefebvre","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib54","first-page":"1081","article-title":"Inhibition of \u03b2-lactamases of mycobacteria by avibactam and clavulanate","volume":"72","author":"Soroka","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib55","article-title":"In vitro activity of the new -lactamase inhibitors relebactam and vaborbactam in combination with -lactams against Mycobacterium abscessus complex clinical isolates","volume":"63","author":"Kaushik","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib56","doi-asserted-by":"crossref","first-page":"6904","DOI":"10.1128\/AAC.00459-15","article-title":"Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models","volume":"59","author":"Obreg\u00f3n-Henao","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib57","doi-asserted-by":"crossref","first-page":"e00114","DOI":"10.1128\/AAC.00114-20","article-title":"Efficacy of bedaquiline, alone or in combination with imipenem, against Mycobacterium abscessus in C3HeB\/FeJ mice","volume":"64","author":"Le Moigne","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib58","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2022.102268_bib59","doi-asserted-by":"crossref","DOI":"10.1242\/dmm.049159","article-title":"Mycobacteriophage-antibiotic therapy promotes enhanced clearance of drug-resistant Mycobacterium abscessus","volume":"14","author":"Johansen","year":"2021","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.tube.2022.102268_bib60","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/s41591-021-01403-9","article-title":"Potent antibody-mediated neutralization limits bacteriophage treatment of a pulmonary Mycobacterium abscessus infection","volume":"27","author":"Dedrick","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.tube.2022.102268_bib61","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02234-18","article-title":"In vitro synergism of rifabutin with clarithromycin, imipenem, and tigecycline against the Mycobacterium abscessus complex","volume":"63","author":"Cheng","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib62","first-page":"600","article-title":"Administration of substances to laboratory animals: routes of administration and factors to consider","volume":"50","author":"Turner","year":"2011","journal-title":"J Am Assoc Lab Anim Sci"},{"key":"10.1016\/j.tube.2022.102268_bib63","doi-asserted-by":"crossref","first-page":"6390","DOI":"10.1016\/j.bmc.2016.11.008","article-title":"Animal models in the pharmacokinetic\/pharmacodynamic evaluation of antimicrobial agents","volume":"24","author":"Zhao","year":"2016","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.tube.2022.102268_bib64","first-page":"207","article-title":"The Mighty Mouse: the impact of rodents on advances in biomedical research","volume":"110","author":"Bryda","year":"2013","journal-title":"Mo Med"},{"key":"10.1016\/j.tube.2022.102268_bib65","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1093\/ilar\/ilw021","article-title":"Mouse models for drug discovery. Can new tools and technology improve translational power?","volume":"57","author":"Zuberi","year":"2016","journal-title":"ILAR J"},{"key":"10.1016\/j.tube.2022.102268_bib66","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.clinthera.2019.08.010","article-title":"Mouse models as resources for studying infectious diseases","volume":"41","author":"Sarkar","year":"2019","journal-title":"Clin Therapeut"},{"key":"10.1016\/j.tube.2022.102268_bib67","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2174\/1874279300802010059","article-title":"Assessment of the efficacy of new anti-tuberculosis drugs","volume":"2","author":"Mitchison","year":"2008","journal-title":"Open Infect Dis J"},{"key":"10.1016\/j.tube.2022.102268_bib68","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.5588\/ijtld.12.0277","article-title":"New drugs for the treatment of tuberculosis: hope and reality [State of the Art Series. New tools. Number 2 in the series]","volume":"16","author":"Grosset","year":"2012","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.tube.2022.102268_bib69","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1128\/AAC.00912-12","article-title":"Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis","volume":"56","author":"Rosenthal","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib70","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1128\/AAC.00595-10","article-title":"Comparative studies evaluating mouse models used for efficacy testing of experimental drugs against Mycobacterium tuberculosis","volume":"55","author":"De Groote","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib71","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1093\/infdis\/jiab101","article-title":"Predictive modeling to study the treatment-shortening potential of novel tuberculosis drug regimens, towards bundling of preclinical data","volume":"225","author":"Mudde","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib72","first-page":"1","article-title":"A mouse model of pulmonary Mycobacteroides abscessus infection","volume":"10","author":"Maggioncalda","year":"2020","journal-title":"Nat Sci Reports"},{"key":"10.1016\/j.tube.2022.102268_bib73","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.1128\/AAC.00217-12","article-title":"Evaluation of a mouse model of necrotic granuloma formation using C3HeB\/FeJ mice for testing of drugs against Mycobacterium tuberculosis","volume":"56","author":"Driver","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib74","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1242\/dmm.019570","article-title":"Presence of multiple lesion types with vastly different microenvironments in C3HeB\/FeJ mice following aerosol infection with Mycobacterium tuberculosis","volume":"8","author":"Irwin","year":"2015","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.tube.2022.102268_bib75","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1242\/dmm.019513","article-title":"Heterogeneous disease progression and treatment response in a C3HeB\/FeJ mouse model of tuberculosis","volume":"8","author":"Lanoix","year":"2015","journal-title":"Dis Model Mech"},{"key":"10.1016\/j.tube.2022.102268_bib76","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1093\/infdis\/jit614","article-title":"In vivo evaluation of antibiotic activity against Mycobacterium abscessus","volume":"209","author":"Lerat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib77","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3389\/fmicb.2020.00371","article-title":"Rifabutin: a repurposing candidate for Mycobacterium abscessus lung disease","volume":"11","author":"Dick","year":"2020","journal-title":"Front Microbiol"},{"key":"10.1016\/j.tube.2022.102268_bib78","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/jid.1953.18","article-title":"An unusual acid-fast infection of the knee with subcutaneous, abscess-like lesions of the gluteal region","volume":"20","author":"Moore","year":"1953","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.tube.2022.102268_bib79","series-title":"Mol. Genet. Mycobact.","first-page":"313","article-title":"Some common methods in mycobacterial genetics","author":"Larsen","year":"2000"},{"key":"10.1016\/j.tube.2022.102268_bib80","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00388-19","article-title":"Treatment-Shortening effect of a novel regimen combining clofazimine and high-dose rifapentine in pathologically distinct mouse models of tuberculosis","volume":"63","author":"Saini","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib81","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01881-19","article-title":"Assessment of clofazimine and TB47 combination activity against Mycobacterium abscessus using a bioluminescent approach","volume":"64","author":"Liu","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib82","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1093\/jac\/dkw417","article-title":"Clofazimine has delayed antimicrobial activity against Mycobacterium tuberculosis both in vitro and in vivo","volume":"72","author":"Ammerman","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib83","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.ijantimicag.2009.12.008","article-title":"High efficacy of clofazimine and its synergistic effect with amikacin against rapidly growing mycobacteria","volume":"35","author":"Shen","year":"2010","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.tube.2022.102268_bib84","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1128\/AAC.01505-12","article-title":"In vitro synergy between clofazimine and amikacin in treatment of nontuberculous mycobacterial disease","volume":"56","author":"van Ingen","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib85","doi-asserted-by":"crossref","first-page":"O1124","DOI":"10.1111\/1469-0691.12780","article-title":"In vitro evaluation of a new drug combination against clinical isolates belonging to the Mycobacterium abscessus complex","volume":"20","author":"Singh","year":"2014","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.tube.2022.102268_bib86","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00072-18","article-title":"In vitro activity of clofazimine against nontuberculous mycobacteria isolated in beijing, China","volume":"62","author":"Luo","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib87","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.chest.2020.07.040","article-title":"Minimal inhibitory concentration of clofazimine among clinical isolates of nontuberculous mycobacteria and its impact on treatment outcome","volume":"159","author":"Kwak","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.tube.2022.102268_bib88","doi-asserted-by":"crossref","DOI":"10.1136\/thoraxjnl-2015-207983","article-title":"US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis","volume":"71","author":"Floto","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.tube.2022.102268_bib89","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J Basic Clin Pharm"},{"key":"10.1016\/j.tube.2022.102268_bib90","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1513\/AnnalsATS.202003-222CME","article-title":"Summary for clinicians: 2020 clinical practice guideline summary for the treatment of nontuberculous mycobacterial pulmonary disease","volume":"17","author":"Kurz","year":"2020","journal-title":"Ann Am Thorac Soc"},{"key":"10.1016\/j.tube.2022.102268_bib91","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01943-19","article-title":"Rifabutin is active against Mycobacterium abscessus in mice","volume":"64","author":"Dick","year":"2020","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib92","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1164\/ajrccm\/136.2.329","article-title":"Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections","volume":"136","author":"Gangadharam","year":"1987","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.tube.2022.102268_bib93","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1128\/AAC.37.8.1690","article-title":"Clarithromycin, minocycline, and rifabutin treatments before and after infection of C57BL\/6 mice with Mycobacterium avium","volume":"37","author":"Lazard","year":"1993","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib94","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ijid.2016.12.027","article-title":"Minimum inhibitory concentration distributions for Mycobacterium avium complex\u2014towards evidence-based susceptibility breakpoints","volume":"55","author":"Sch\u00f6n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib95","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00155-17","article-title":"Rifabutin is active against Mycobacterium abscessus complex","volume":"61","author":"Aziz","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.tube.2022.102268_bib96","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1186\/1471-2202-9-S3-S7","article-title":"Requirements for a lead compound to become a clinical candidate","volume":"9","author":"Hefti","year":"2008","journal-title":"BMC Neurosci"},{"key":"10.1016\/j.tube.2022.102268_bib97","doi-asserted-by":"crossref","DOI":"10.4212\/cjhp.v68i4.1472","article-title":"Addressing concerns about changing the route of antimicrobial administration from intravenous to oral in adult inpatients","volume":"68","author":"B\u00e9\u00efque","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"10.1016\/j.tube.2022.102268_bib98","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/jac\/dky452","article-title":"Sequential intravenous-to-oral outpatient antibiotic therapy for MRSA bacteraemia: one step closer","volume":"74","author":"Jorgensen","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib99","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1093\/cid\/ciy916","article-title":"Early oral switch to linezolid for low-risk patients with Staphylococcus aureus bloodstream infections: a propensity-matched cohort study","volume":"69","author":"Willekens","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib100","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/jamainternmed.2018.6226","article-title":"Association of 30-day mortality with oral step-down vs continued intravenous therapy in patients hospitalized with enterobacteriaceae bacteremia","volume":"179","author":"Tamma","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.tube.2022.102268_bib101","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s15010-017-0997-0","article-title":"The \u201cChoosing Wisely\u201d initiative in infectious diseases","volume":"45","author":"Lehmann","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.tube.2022.102268_bib102","article-title":"Central line catheters and associated complications: a review","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"10.1016\/j.tube.2022.102268_bib103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.4103\/0976-500X.130042","article-title":"Switch over from intravenous to oral therapy: a concise overview","volume":"5","author":"Cyriac","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"key":"10.1016\/j.tube.2022.102268_bib104","doi-asserted-by":"crossref","first-page":"102058","DOI":"10.1016\/j.pupt.2021.102058","article-title":"Clofazimine for treatment of multidrug-resistant non-tuberculous mycobacteria","volume":"70","author":"Pfaeffle","year":"2021","journal-title":"Pulm Pharmacol Ther."},{"key":"10.1016\/j.tube.2022.102268_bib105","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1177\/106002809102500513","article-title":"Clofazimine: a review of its use in leprosy and Mycobacterium avium complex infection","volume":"25","author":"Garrelts","year":"1991","journal-title":"DICP"},{"key":"10.1016\/j.tube.2022.102268_bib106","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.5588\/ijtld.12.0144","article-title":"Systematic review of clofazimine for the treatment of drug-resistant tuberculosis [Review article]","volume":"17","author":"Gopal","year":"2013","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.tube.2022.102268_bib107","doi-asserted-by":"crossref","first-page":"ofx147","DOI":"10.1093\/ofid\/ofx147","article-title":"Clofazimine in nontuberculous mycobacterial infections: a growing niche","volume":"4","author":"McGuffin","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tube.2022.102268_bib108","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1093\/jac\/dku007","article-title":"Erm(41)-dependent inducible resistance to azithromycin and clarithromycin in clinical isolates of Mycobacterium abscessus","volume":"69","author":"Maurer","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.tube.2022.102268_bib109","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1128\/AAC.00260-15","article-title":"Pharmacokinetics and pharmacodynamics of clofazimine in a mouse model of tuberculosis","volume":"59","author":"Swanson","year":"2015","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222001056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1472979222001056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:46:07Z","timestamp":1761468367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1472979222001056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":109,"alternative-id":["S1472979222001056"],"URL":"https:\/\/doi.org\/10.1016\/j.tube.2022.102268","relation":{},"ISSN":["1472-9792"],"issn-type":[{"value":"1472-9792","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clofazimine as a comparator for preclinical efficacy evaluations of experimental therapeutics against pulmonary M. abscessus infection in mice","name":"articletitle","label":"Article Title"},{"value":"Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tube.2022.102268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102268"}}